Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate ...

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic s...

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases

 WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regres...

JMP Securities analyst Reni Benjamin initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform rati...

HC Wainwright & Co. analyst Andres Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 ...

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the...